iCAD (NASDAQ:ICAD) Shares Pass Above 200-Day Moving Average of $6.38

iCAD Inc (NASDAQ:ICAD)’s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.38 and traded as high as $6.82. iCAD shares last traded at $6.82, with a volume of 101 shares.

Separately, ValuEngine lowered shares of iCAD from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st.

The business’s 50 day moving average is $7.01 and its 200 day moving average is $6.42. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.85 and a current ratio of 2.00. The stock has a market cap of $130.98 million, a price-to-earnings ratio of -18.13 and a beta of 1.12.

iCAD (NASDAQ:ICAD) last posted its quarterly earnings data on Wednesday, October 30th. The technology company reported ($0.10) EPS for the quarter, hitting analysts’ consensus estimates of ($0.10). iCAD had a negative net margin of 46.85% and a negative return on equity of 78.90%. The firm had revenue of $7.86 million during the quarter, compared to analyst estimates of $7.43 million. Research analysts expect that iCAD Inc will post -0.58 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the stock. United Capital Financial Advisers LLC boosted its stake in iCAD by 6.7% in the 2nd quarter. United Capital Financial Advisers LLC now owns 57,765 shares of the technology company’s stock worth $368,000 after purchasing an additional 3,625 shares during the period. Tower Research Capital LLC TRC acquired a new stake in shares of iCAD during the 2nd quarter valued at $54,000. Cadence Capital Management LLC acquired a new stake in shares of iCAD during the 3rd quarter valued at $73,000. BlackRock Inc. boosted its stake in shares of iCAD by 2.8% during the 2nd quarter. BlackRock Inc. now owns 431,521 shares of the technology company’s stock valued at $2,750,000 after buying an additional 11,757 shares during the period. Finally, Worth Venture Partners LLC acquired a new stake in shares of iCAD during the 2nd quarter valued at $92,000. 23.86% of the stock is owned by hedge funds and other institutional investors.


iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.

Further Reading: What is a Futures Contract?

Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.